Rejuvenate Bio announced new preclinical research published to the preprint server bioRxiv that evaluates how partial reprogramming could be a potential treatment in the elderly to reverse age-associated diseases and potentially extend human lifespan.
New Preclinical Research Evaluating Cellular Reprogramming for Age Reversal
Previous
Previous
Rejuvenate Bio Announces Preclinical Data for Gene Therapy Candidate RJB-0402 for the Treatment of Arrhythmogenic Cardiomyopathy
Next
Next